Sagetis Biotech is devoted to developing an innovative polymeric technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. 
Privately funded and based in Barcelona, Sagetis Biotech is developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.

The VIROSHIELD™ coating technology is able to modify the behavior of oncolytic viruses, improving their therapeutic effect by different means. The coated oncolytic adenoviruses are protected against pre-existing neutralizing antibodies, by masking their surface antigenic epitopes, while preserving their transduction capability.

Viroshield technology
Viroshield technology
Team effort
Featured Posts